BioTime Inc. (BTX)

2.35
0.05 2.17
AMEX : Health Technology
Prev Close 2.30
Open 2.33
Day Low/High 2.28 / 2.36
52 Wk Low/High 2.08 / 3.21
Volume 1.46M
Avg Volume 348.90K
Exchange AMEX
Shares Outstanding 126.87M
Market Cap 301.96M
EPS -0.20
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

AgeX Therapeutics Appoints John F. Mauldin To Board Of Directors

AgeX Therapeutics Appoints John F. Mauldin To Board Of Directors

AgeX Therapeutics, Inc., a subsidiary of  BioTime, Inc.

BioTime Announces $1.9 Million Grant For Continued Development Of OpRegen® For Dry-AMD

BioTime Announces $1.9 Million Grant For Continued Development Of OpRegen® For Dry-AMD

BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, has been awarded a new grant for 2018 of up to 6.

BioTime Further Expands OpRegen® Clinical Trial In Dry-AMD With The Opening Of Two Additional U.S. Sites

BioTime Further Expands OpRegen® Clinical Trial In Dry-AMD With The Opening Of Two Additional U.S. Sites

BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced the expansion of its ongoing Phase I/IIa clinical trial for OpRegen ®, with the addition of two new U.

BioTime Reports First Quarter Results And Recent Corporate Accomplishments

BioTime Reports First Quarter Results And Recent Corporate Accomplishments

BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today reported financial results for the first quarter ended March 31, 2018 and recent corporate accomplishments.

AgeX Announces NIH Grant Award

AgeX Announces NIH Grant Award

AgeX Therapeutics, Inc., a subsidiary of BioTime, Inc.

BioTime Presents Updated OpRegen® Clinical Trial Data At ARVO

BioTime Presents Updated OpRegen® Clinical Trial Data At ARVO

BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that an abstract related to one of its lead programs, OpRegen ® for dry-AMD, was presented at the Association for Research in...

BioTime To Announce First Quarter 2018 Results On May 10, 2018

BioTime To Announce First Quarter 2018 Results On May 10, 2018

BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that it will release first quarter 2018 financial and operating results on Thursday, May 10, 2018, after the close of the U.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ADES, ALCO, ARTX, EVI, FNJN, INXN, KLXI, KODK, TGEN, XOXO Downgrades: BTX, CCRN, NFBK, WEB Initiations: METC Read on to get TheStreet Quant Ratings' detailed report:

BioTime Announces Cash Sale Of Ascendance Biotechnology

BioTime Announces Cash Sale Of Ascendance Biotechnology

BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that IVT Holdings acquired Ascendance Biotechnology, Inc.

BioTime Reports Fourth Quarter And Fiscal 2017 Results

BioTime Reports Fourth Quarter And Fiscal 2017 Results

BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today reported financial results for the fourth quarter and fiscal year ended December 31, 2017.

Commit To Buy BioTime At $2, Earn 14.4% Annualized Using Options

Commit To Buy BioTime At $2, Earn 14.4% Annualized Using Options

Investors considering a purchase of BioTime Inc stock, but cautious about paying the going market price of $2.69/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the September put at the $2 strike, which has a bid at the time of this writing of 15 cents.

BioTime Submits CE Mark Application For European Approval Of Renevia®

BioTime Submits CE Mark Application For European Approval Of Renevia®

BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on addressing degenerative diseases, announced today the submission of a design dossier application for CE Mark approval to market...

BioTime Announces DSMB Approval To Proceed To Cohort 4 Of The OpRegen® Clinical Trial

BioTime Announces DSMB Approval To Proceed To Cohort 4 Of The OpRegen® Clinical Trial

BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on addressing degenerative diseases, today announced that the independent Data Safety Monitoring Board (DSMB) has approved initiation of the...

BioTime To Announce Fourth Quarter And Fiscal 2017 Results On March 15, 2018

BioTime To Announce Fourth Quarter And Fiscal 2017 Results On March 15, 2018

BioTime, Inc. (NYSE American: BTX), a late stage clinical biotechnology company focused on developing and commercializing products addressing degenerative diseases, today announced that it will release fourth quarter and...

AgeX Therapeutics CEO Dr. Michael D. West To Present At Three Conferences In March 2018

AgeX Therapeutics CEO Dr. Michael D. West To Present At Three Conferences In March 2018

AgeX Therapeutics, Inc., a subsidiary of BioTime, Inc.

BioTime To Present At The Raymond James 39th Annual Institutional Investor Conference

BioTime To Present At The Raymond James 39th Annual Institutional Investor Conference

BioTime, Inc. (NYSE American: BTX), a late-stage, clinical biotechnology company developing and commercializing products addressing degenerative diseases, today announced that Russell Skibsted, Chief Financial Officer of...

BioTime Announces Appointment Of Gary S. Hogge, DVM, MS, PhD, As Sr. Vice President, Clinical And Medical Affairs

BioTime Announces Appointment Of Gary S. Hogge, DVM, MS, PhD, As Sr. Vice President, Clinical And Medical Affairs

BioTime, Inc. (NYSE American: BTX), a late-stage, clinical biotechnology company developing and commercializing products addressing degenerative diseases, today announced the appointment of Gary S.

BioTime Appoints Cavan Redmond To Its Board Of Directors

BioTime Appoints Cavan Redmond To Its Board Of Directors

BioTime, Inc. (NYSE American: BTX), a late-stage, clinical biotechnology company developing and commercializing products addressing degenerative diseases, announced the appointment of Cavan Redmond as an independent...

Data From BioTime's OpRegen® And Vision Restoration Programs To Be Presented At ARVO 2018

Data From BioTime's OpRegen® And Vision Restoration Programs To Be Presented At ARVO 2018

BioTime, Inc. (NYSE American: BTX), a late-stage, clinical biotechnology company developing and commercializing products addressing degenerative diseases, today announced that two abstracts have been accepted and will be...

BioTime To Participate At The BIO CEO And Investor Conference In New York, February 12th And 13th 2018

BioTime To Participate At The BIO CEO And Investor Conference In New York, February 12th And 13th 2018

BioTime, Inc. (NYSE American: BTX), a late-stage, clinical biotechnology company developing and commercializing products addressing degenerative diseases, today announced that Adi Mohanty, Co-Chief Executive Officer of...

Commit To Buy BioTime At $2, Earn 12% Annualized Using Options

Commit To Buy BioTime At $2, Earn 12% Annualized Using Options

Investors considering a purchase of BioTime Inc shares, but cautious about paying the going market price of $2.82/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the September put at the $2 strike, which has a bid at the time of this writing of 15 cents.

Renevia® Data From The Successful Pivotal Trial To Be Presented At The IMCAS Conference

Renevia® Data From The Successful Pivotal Trial To Be Presented At The IMCAS Conference

BioTime, Inc. (NYSE American: BTX), a late-stage, clinical biotechnology company developing and commercializing products addressing degenerative diseases, today announced that detailed data from the successful pivotal...

BioTime To Present At The Noble Capital Markets 14th Annual Institutional Investor Conference In Fort Lauderdale, January 29, 2018

BioTime To Present At The Noble Capital Markets 14th Annual Institutional Investor Conference In Fort Lauderdale, January 29, 2018

BioTime, Inc. (NYSE American: BTX), a late-stage, clinical biotechnology company developing and commercializing products addressing degenerative diseases, today announced that Russell Skibsted, Chief Financial Officer, will...

BioTime Announces Clinical And Corporate Milestone Targets For 2018

BioTime Announces Clinical And Corporate Milestone Targets For 2018

BioTime, Inc. (NYSE American: BTX), a late-stage, clinical biotechnology company developing and commercializing products addressing degenerative diseases, today announced its 2018 clinical and corporate milestone targets.

BioTime Announces Issuance Of 41 New Patents To Expand And Bolster Its Patent Estate

BioTime Announces Issuance Of 41 New Patents To Expand And Bolster Its Patent Estate

BioTime, Inc. (NYSE American: BTX), a late-stage, clinical biotechnology company developing and commercializing products addressing degenerative diseases, today announced the issuance of 41 new patents over the past 12...

TheStreet Quant Rating: D (Sell)